Tvardi Therapeutics/$TVRD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Tvardi Therapeutics
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Ticker
$TVRD
Sector
Primary listing
Employees
11
Headquarters
Website
TVRD Metrics
BasicAdvanced
$38M
-
-$3.23
-
-
Price and volume
Market cap
$38M
52-week high
$43.65
52-week low
$3.85
Average daily volume
534K
Financial strength
Current ratio
3.482
Quick ratio
3.303
Long term debt to equity
0.413
Total debt to equity
0.818
Profitability
EBITDA (TTM)
-29.868
Management effectiveness
Return on assets (TTM)
-72.68%
Return on equity (TTM)
-135.64%
Valuation
Price to book
1.36
Price to tangible book (TTM)
1.37
Price to free cash flow (TTM)
-1.697
Free cash flow yield (TTM)
-58.93%
Free cash flow per share (TTM)
-2.375
Growth
Earnings per share change (TTM)
-45.86%
TVRD News
AllArticlesVideos
Investors in Tvardi Therapeutics, Inc. (TVRD) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today
Newsfile Corp4 days ago
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Newsfile Corp4 days ago
TVRD SECURITIES ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Newsfile Corp6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tvardi Therapeutics stock?
Tvardi Therapeutics (TVRD) has a market cap of $38M as of November 17, 2025.
What is the P/E ratio for Tvardi Therapeutics stock?
The price to earnings (P/E) ratio for Tvardi Therapeutics (TVRD) stock is 0 as of November 17, 2025.
Does Tvardi Therapeutics stock pay dividends?
No, Tvardi Therapeutics (TVRD) stock does not pay dividends to its shareholders as of November 17, 2025.
When is the next Tvardi Therapeutics dividend payment date?
Tvardi Therapeutics (TVRD) stock does not pay dividends to its shareholders.
What is the beta indicator for Tvardi Therapeutics?
Tvardi Therapeutics (TVRD) does not currently have a Beta indicator.